Global Retirement Partners LLC decreased its stake in shares of Sanofi (NASDAQ:SNY – Get Rating) by 8.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,268 shares of the company’s stock after selling 289 shares during the period. Global Retirement Partners LLC’s holdings in Sanofi were worth $141,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of SNY. US Bancorp DE grew its holdings in Sanofi by 10.1% in the 2nd quarter. US Bancorp DE now owns 85,318 shares of the company’s stock valued at $4,268,000 after buying an additional 7,809 shares during the last quarter. Assetmark Inc. increased its position in Sanofi by 55.1% during the third quarter. Assetmark Inc. now owns 57,990 shares of the company’s stock worth $2,205,000 after acquiring an additional 20,596 shares during the period. Greenleaf Trust boosted its holdings in Sanofi by 8.2% in the 2nd quarter. Greenleaf Trust now owns 11,232 shares of the company’s stock valued at $562,000 after purchasing an additional 848 shares during the period. Rockefeller Capital Management L.P. grew its position in Sanofi by 4.8% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 193,940 shares of the company’s stock worth $7,372,000 after purchasing an additional 8,946 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Sanofi by 250.9% during the 3rd quarter. SG Americas Securities LLC now owns 72,164 shares of the company’s stock worth $2,744,000 after purchasing an additional 51,598 shares during the period. Institutional investors own 10.04% of the company’s stock.
Sanofi Stock Performance
Shares of NASDAQ SNY opened at $48.53 on Wednesday. The stock has a market capitalization of $123.02 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 1.14 and a beta of 0.56. Sanofi has a 52 week low of $36.91 and a 52 week high of $58.10. The stock has a 50 day moving average price of $47.23 and a 200 day moving average price of $42.73. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on SNY shares. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, December 16th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a report on Tuesday, December 13th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, December 2nd. StockNews.com began coverage on shares of Sanofi in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Barclays dropped their price objective on shares of Sanofi from €105.00 ($114.13) to €85.00 ($92.39) and set an “equal weight” rating for the company in a research report on Friday, October 14th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.